Cardiopulmonary Bypass
Conditions
Keywords
Neonates
Brief summary
The primary goal of this investigation is to determine the ability of recombinant activated factor VII (rFVIIa) and prothrombin complex concentrate (PCC) to improve thrombin generation in neonatal plasma after CPB.
Detailed description
In this investigation, the investigators propose a comparison in vitro of the ability of rFVIIa with that of PCC to increase thrombin generation in neonatal plasma after CPB. A pre-cardiopulmonary bypass (CPB) baseline blood sample will be obtained. After the termination of CPB and the administration of one round of protamine, platelets and fibrinogen (standard of care), a second blood sample will be drawn. All samples will be centrifuged to yield platelet rich plasma and stored until processing. In the pre-CPB sample, baseline thrombin generation will be measured. The post-CPB sample will be divided into three aliquots to measure thrombin generation under three different circumstances: the first will serve as a control, the second will include rFVIIa and the third PCC.
Interventions
Plasma will be spiked in vitro with recombinant activated factor VII to assess increases in thrombin generation with and without the drug
Plasma will be spiked in vitro with prothrombin complex concentrate to determine increases in thrombin generation with and without the drug
Sponsors
Children's Research Oversight Committee Funds
Emory University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 30 Days
Healthy volunteers
No
Inclusion criteria
1. Full-term neonates (36-42 weeks gestational age) 2. Apgar score of 7 or more at 5 minutes after delivery 3. Neonates undergoing elective cardiac surgery requiring CPB at Children's Healthcare of Atlanta at Egleston 4. Parents willing to participate, and able to understand and sign the provided informed consent
Exclusion criteria
1. Preterm neonates (less than 36 weeks gestation) 2. Apgar score of less than 6 at 5 minutes after birth 3. Emergent procedure 4. Patients undergoing cardiac surgery not requiring CPB 5. Neonates with a known coagulation defect or coagulopathy 6. Mother with a known coagulation defect or coagulopathy 7. Parents unwilling to participate or unable to understand and sign the provided informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Peak thrombin Generation | one year | The primary outcome measure is the peak amount of thrombin generated (measured in nM) as determined by the Thrombinoscope with rFVIIa as compared to PCC. |
Countries
United States
Outcome results
None listed